Brochures, Forms, and Reports
UNITY™ sgNIPT has shown > 98.5% sensitivity and >99% speciﬁcity in a peer reviewed publication.
It has also shown 100% concordance with newborn screen results in NIH-sponsored clinical study with Baylor College of Medicine and a study with University of Alabama Birmingham.
Single-Molecule Accuracy Powered by QCT™
Using QCT™ molecular counting technology, UNITY™ is able to differentiate homozygous affected fetus (colored bars) from carrier fetus (gray bar). In addition, UNITY™ performs a paternal allele assay to detect a fetus at-risk to be compound heterozygous for CFTR or HBB at >98% detection rate.
Exemplary Readout. Chromosome 21 Ratio: euploid vs trisomy 21
UNITY™ sgNIPT and Aneuploidy + RhD NIPT use synthetic molecules and computational decoding in the bioinformatics stage to reduce the assay amplification noise down to the theoretical limit. Thanks to these proprietary technologies, UNITY™ can uniquely offer reflex sgNIPT and Rh NIPT solutions.
The world’s only next generation sequencing-based fetal RhD cell-free DNA test
Each assay includes QCT™ (Quantitative Counting Template) controls to ensure the Rh- result is due to the true absence of RHD gene, not an assay failure. Internal clinical study showed 100% accuracy in making Rh- calls.